Loading...
Loading...
RCUS| Name | Value |
|---|---|
| Revenues | 25.0M |
| Cost of Revenue | 4.0M |
| Gross Profit | 21.0M |
| Operating Expense | 111.0M |
| Operating I/L | -86.0M |
| Other Income/Expense | 8.0M |
| Interest Income | 9.0M |
| Pretax | -78.0M |
| Income Tax Expense | 2.0M |
| Net Income/Loss | -80.0M |
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapies. The company's product pipeline includes Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, and Zimberelimab, an anti-PD-1 antibody, both in various stages of clinical trials. Additionally, Arcus Biosciences is developing Domvanalimab, an anti-TIGIT monoclonal antibody, Quemliclustat, a small-molecule CD73 inhibitor, and AB521, an oral and small molecule HIF-2a inhibitor, all targeted at treating different types of cancer. The company has collaboration agreements with Strata Oncology, Inc., AstraZeneca, BVF Partners L.P, Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to further develop and evaluate its cancer therapies.
